Science

CCMB develops low-cost novel coronavirus test

Our Burea Hyderabad | Updated on June 11, 2020 Published on June 11, 2020

Researchers at the Centre for Cellular and Molecular Biology (CCMB) have developed a new low-cost and low-tech required test for SARS-CoV-2 testing known as reverse transcription nested PCR (RT-nPCR) test.

This test does not require real-time quantitative RT-qPCR. The RT-nPCR developed by the CCMB research team has shown comparable performance to the standard RT-qPCR test. The nested PCR (RT-nPCR) approach does not depend on RT-qPCR but uses standard RT-PCR as part of an endpoint assay.

In the course of comparing the results of both tests, researchers found that the standard RT-qPCR test can have low detection efficiency (less than 50%) in a real testing scenario, which may be due to low viral representation in many samples. This finding brought home the importance of monitoring detection efficiency directly in test environments.

“We developed and tested an RT-nPCR protocol comprising a multiplex primary RT-PCR for amplification of four SARS-CoV-2 amplicons and a control human amplicon followed by a secondary nested PCR for individual amplicons. We also examined the use of RT-nPCR in pooled testing and in direct amplification without RNA isolation,” said Rakesh Mishra, Director, CCMB.

The RNA isolated from nasopharyngeal swab samples that had been previously tested using one of the two RT-qPCR tests was examined using RT-nPCR and the results were compared. It was found that taking both standard RT-qPCR tests together, the RT-nPCR test was able to identify 90% of the detected samples as positive by RT-qPCR.

It also detected 13% samples as positive among samples that were negative by the standard RT-qPCR test (likely false negatives). Based on the experimentally measured false-negative rate by RT-nPCR tests from this study, it was estimated that as many as 50% of positive samples may escape detection in single pass testing by RT-qPCR in an actual testing scenario.

The Indian Council of Medical Research (ICMR) has recommended only reverse transcription-polymerase chain reaction (RT-qPCR) test for novel coronavirus testing, according to a statement.

“This new test is awaiting approval from ICMR. We might ask ICMR to use this test in those places where there are no RT-qPCR machines,” Mishra said.

Published on June 11, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
SARS-CoV-2 has infected less than 1% of sample population: ICMR survey